SCHEMBL5577324

SCHEMBL5577324

N#CC1(c2ccc(CNC(=O)c3ccc(Cl)cc3)cc2)CCN(Cc2ccc(F)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKAA2 P54646 2/20 0.49
POLB P06746 1/20 0.47
OPRM1 P35372 1/20 0.46
MCHR1 Q99705 2/20 0.46
ALDH1A1 P00352 1/20 0.46
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
CXCR3 P49682 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
OPRL1 P41146 1/20 0.45
CHRM3 P20309 1/20 0.45
GPR183 P32249 1/20 0.45
CYP2D6 P10635 1/20 0.44
CHRM1 P11229 1/20 0.44
HTR2A P28223 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5577349 0.90 CHRM3 (0.52) PRKAA2OPRM1ALDH1A1OPRL1CHRM3
SCHEMBL5577372 0.85 GPR183 (0.44) PRKAA2MCHR1ALDH1A1OPRL1CHRM3
SCHEMBL5577668 0.85 PDE4A (0.52) POLBMCHR1ALDH1A1SMN1; SMN2
SCHEMBL5577432 0.85 PRKAA2 (0.47) PRKAA2MCHR1CXCR3CHRM3
SCHEMBL5577487 0.83 PRKAA2 (0.47) PRKAA2MCHR1CXCR3GPR183CYP2D6
SCHEMBL5577711 0.82 PRKAA2 (0.46) PRKAA2MCHR1CXCR3GPR183CYP2D6
SCHEMBL5577441 0.82 MCHR1 (0.45) PRKAA2MCHR1CXCR3CHRM3
SCHEMBL5577480 0.82 MT-CO2 (0.54) PRKAA2OPRM1MCHR1SMN1; SMN2OPRL1
SCHEMBL6355362 0.77 POLB (0.72) POLBSMN1; SMN2
SCHEMBL5577460 0.77 CHRM3 (0.50) ALDH1A1DRD4SMN1; SMN2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-22 US disclosed
EP-1616862-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof HLA-DRB1, MIF, HLA-C PRKAA2 4492/4885POLB 3375/4885OPRM1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.